10-Q: Ovid Therapeutics Faces Going Concern Doubt Amid Losses

Ovid Therapeutics reported increased net losses and substantial doubt about its ability to continue as a going concern, despite a one-time revenue boost from a licensing agreement.

Summary

• Ovid Therapeutics reported a net loss of $14.9 million for the six months ended June 30, 2025, compared to a net loss of $3.2 million for the same period in 2024.
• Total revenue significantly increased to $6.4 million for the six months ended June 30, 2025, up from $0.3 million in the prior year, primarily due to a $6.3 million payment from the Marinus License Agreement amendment.
• Research and development expenses decreased by $9.9 million to $13.1 million for the six months ended June 30, 2025, mainly due to the pause of the OV888 (GV101) program and organizational restructuring.
• General and administrative expenses decreased by $4.4 million to $10.9 million for the six months ended June 30, 2025, driven by cost reduction strategies and reduced headcount.
• As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $38.3 million, which is not sufficient to fund projected operating expenses for the next 12 months.
• The company has an accumulated deficit of $319.2 million as of June 30, 2025.
• Nasdaq granted an extension until February 9, 2026, for the company to regain compliance with the minimum $1.00 bid price requirement, following a transfer to the Nasdaq Capital Market.
• Stockholders approved a reverse stock split at a ratio of 1-for-10 to 1-for-40, at the Board's discretion, to help regain Nasdaq compliance.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, with substantial doubt about its going concern ability and insufficient cash for the next 12 months. While expense reductions are noted, these are coupled with program pauses and a major partnered program discontinuation. The increased net loss and ongoing Nasdaq compliance issues highlight a challenging outlook, despite a one-time revenue boost.

Positives

• Revenue increased significantly to $6.4 million for the six months ended June 30, 2025, primarily due to a $6.3 million one-time payment from the Marinus License Agreement amendment.
• Net cash used in operating activities decreased to $15.1 million for the six months ended June 30, 2025, compared to $30.9 million in the prior year, indicating improved cash burn efficiency.
• Research and development expenses decreased by $9.9 million, and general and administrative expenses decreased by $4.4 million, reflecting successful cost reduction efforts and organizational restructuring.
• The company fully recovered $1.8 million from a fraudulent funds transfer in January 2025, which was previously recorded as a loss.

Negatives

• The company reported a net loss of $14.9 million for the six months ended June 30, 2025, an increase from $3.2 million in the prior year, indicating continued unprofitability.
• Existing cash, cash equivalents, and marketable securities of $38.3 million are not sufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• The accumulated deficit grew to $319.2 million as of June 30, 2025.
• The OV888 (GV101) program is currently paused, and the soticlestat program (partnered with Takeda) was discontinued after missing primary endpoints in Phase 3 trials.
• The company faces a risk of delisting from Nasdaq if it does not regain compliance with the minimum bid price requirement by February 9, 2026.
• The company is highly dependent on its ability to find additional sources of funding, which may not be available on acceptable terms or at all.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, requiring additional capital that may not be available.
• The company expects to continue incurring substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
• The company is early in its drug development efforts, and success in preclinical or earlier clinical trials does not guarantee future success or regulatory approval.
• Interim and preliminary clinical trial data may change as more patient data becomes available and is subject to audit and verification.
• Preclinical studies and clinical trials are expensive, time-consuming, and involve uncertain outcomes, with potential for substantial delays or failure to demonstrate safety and efficacy.
• The company's future success depends on successfully discovering, developing, and commercializing additional drug candidates.
• Drug candidates may cause undesirable side effects, delaying or preventing regulatory approval, limiting commercial potential, or resulting in negative consequences post-approval.
• Market opportunities for drug candidates may be smaller than anticipated, impacting profitability and growth.
• The company faces substantial competition from major pharmaceutical and biotechnology companies.
• Even if approved, drug candidates may fail to achieve market acceptance by physicians, patients, and third-party payors.
• The company may not obtain or maintain orphan drug designations or exclusivity, limiting potential profitability.
• Approved drug candidates will remain subject to ongoing regulatory oversight, with potential for restrictions or withdrawal of approval.
• Disruptions at the FDA and other government agencies could negatively impact the business.
• The company relies on third parties for manufacturing and clinical trials, posing risks if these parties perform unsatisfactorily.
• The company is highly dependent on its senior management team and ability to attract and retain qualified personnel.
• Information technology systems and data are vulnerable to security incidents, which could lead to adverse impacts.
• The company is subject to stringent and evolving privacy and security laws, with non-compliance risking investigations, litigation, and penalties.
• The ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes or tax law restrictions.
• Failure to satisfy Nasdaq listing requirements could lead to delisting, adversely affecting market liquidity and stock price.
• The market price of common stock is volatile and could result in substantial losses for stockholders.
• Concentration of ownership among executive officers, directors, and principal stockholders may prevent new investors from influencing corporate decisions.
• Provisions in organizational documents and Delaware law could make an acquisition more difficult and prevent attempts to replace current management.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for at least the next several years as it advances current and future drug candidates through preclinical studies and clinical trials, builds its portfolio, seeks marketing approvals, establishes commercial infrastructure, protects intellectual property, and expands personnel. The company's existing cash, cash equivalents, and marketable securities are not sufficient to fund operations for the next 12 months, necessitating additional financing or strategic alternatives.

Management Comments

• Our approach to achieve this goal is scientifically driven, patient focused, and coupled with an integrated and disciplined approach to research, clinical development and business development.
• Our team has significant experience with and understanding of epilepsies and other neurological conditions, and we continue to gain insight into the ways the different molecular mechanisms and pathways underlying these disorders impact the symptoms patients experience.
• We have developed a differentiated pipeline of drug candidates containing three novel mechanisms of action (MoAs) to target seizures and believe we are the only company that holds a portfolio of direct activators of potassium-chloride cotransporter 2 (KCC2).
• We are currently evaluating strategic alternatives, including additional financings or other options such as partnerships or collaborations, strategic alliances, licensing agreements or a combination of any such transactions, which may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.

Industry Context

Ovid Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on small molecule medicines for brain conditions with significant unmet needs, particularly epilepsies, psychiatric, neurodegenerative, and neurodevelopmental conditions. The company aims to differentiate itself with a portfolio of direct activators of KCC2. The industry faces challenges from global economic slowdowns, inflation, supply chain disruptions, and geopolitical tensions, which can impact operating costs and access to capital. Regulatory scrutiny on drug pricing and evolving data privacy laws also add complexity to the operating environment.

Corporate Governance

Legal Proceedings

• The company is not currently involved in any material legal matters arising in the normal course of business.

Related Party Transactions

• In March 2021, the company entered into the Royalty, License and Termination (RLT) Agreement with Takeda Pharmaceutical Company Limited, a greater than 5% holder of Ovid's common stock. Takeda has agreed to standstill provisions, restrictions on stock sales/transfers, and voting obligations on certain matters.

Stakeholder Impact

• **Shareholders**: Face substantial dilution risk from potential future equity offerings and a volatile stock price. The reverse stock split aims to prevent delisting but does not guarantee long-term value. Concentration of ownership by executive officers, directors, and principal stockholders may limit influence of new investors.
• **Employees**: Organizational restructuring in Q2 2024 led to reduced headcount, impacting employee base. Future growth plans require attracting and retaining highly qualified personnel in a competitive market.
• **Customers/Patients**: Development of new small molecule medicines for brain conditions with unmet needs continues, but program pauses (OV888) and discontinuation (soticlestat) may delay or eliminate potential new treatments. Market acceptance of future approved drugs is uncertain.
• **Suppliers/Creditors**: Reliance on third-party manufacturers and CROs introduces supply chain and operational risks. The company's 'going concern' doubt may impact its ability to secure favorable terms with suppliers and creditors.
• **Regulatory Authorities**: The company is subject to ongoing regulatory oversight and compliance with various healthcare laws and regulations, including those related to fraud, abuse, and data privacy. Non-compliance could lead to significant penalties and operational disruptions.

Next Steps

• Continue ongoing and planned preclinical and clinical development of drug candidates.
• Build a portfolio of drug candidates through development, acquisition, or in-license of drugs, candidates, or technologies.
• Initiate preclinical studies and clinical trials for any additional drug candidates, with a third program expected to begin a clinical trial in Q2 2026.
• Seek marketing approvals for current and future drug candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure to commercialize any approved drug candidates.
• Develop, maintain, expand, and protect the intellectual property portfolio.
• Implement operational, financial, and management systems.
• Attract, hire, and retain additional administrative, clinical, regulatory, manufacturing, commercial, and scientific personnel.
• Evaluate strategic alternatives, including additional financings, partnerships, collaborations, or licensing agreements to address liquidity needs.
• Potentially implement a reverse stock split (1-for-10 to 1-for-40) to regain Nasdaq minimum bid price compliance by February 9, 2026.
• Transfer additional licensure related to the Marinus License Agreement within six months of the June 2025 amendment effective date.

Key Dates

Recommendation

The company faces significant financial challenges, including substantial doubt about its ability to continue as a going concern, with current cash reserves insufficient for the next 12 months. While expense management has improved, this is partly due to program pauses and restructuring, and the net loss has increased year-over-year. The discontinuation of the soticlestat program by Takeda is a major setback, and the company's reliance on future capital raises, which may dilute existing shareholders, is a critical concern. The ongoing Nasdaq delisting risk further adds to the negative outlook, making the stock a high-risk investment with limited near-term upside potential.

Keywords

Biopharmaceutical, Brain Conditions, Neurological Disorders, Epilepsy, Psychosis, KCC2 Activators, Clinical Trials, Drug Development, SEC Filing, 10-Q, Financial Results, Liquidity, Going Concern, Nasdaq Compliance, Reverse Stock Split, Licensing Agreement, Research and Development, Operating Expenses, Intellectual Property, Risk Factors